SEOUL, South Korea–(BUSINESS WIRE)– #ADC–AimedBio, a clinical-stage biotech company, announces first patient dosed in Phase I trial of ADC candidate BI 4060107.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.